

Federica Martorana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9610350/publications.pdf>

Version: 2024-02-01

25
papers

622
citations

840776

11
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

839
citing authors

#	ARTICLE	IF	CITATIONS
1	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.	3.7	16
2	Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 343-351.	2.4	6
3	Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience. <i>Pathology Research and Practice</i> , 2022, 232, 153820.	2.3	4
4	Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily. <i>Cancer Management and Research</i> , 2022, Volume 14, 1341-1352.	1.9	5
5	Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.3	2
6	AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. <i>Frontiers in Pharmacology</i> , 2021, 12, 662232.	3.5	109
7	PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103334.	4.4	20
8	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5012-5019.	7.0	10
9	Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7707.	4.1	16
10	The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities. <i>Translational Oncology</i> , 2021, 14, 101104.	3.7	2
11	Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery. <i>Nature Communications</i> , 2021, 12, 5006.	12.8	38
12	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. <i>Diagnostics</i> , 2021, 11, 1502.	2.6	1
13	Radiomics in cervical and endometrial cancer. <i>British Journal of Radiology</i> , 2021, 94, 20201314.	2.2	19
14	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102300.	7.7	8
15	A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors. <i>Molecules</i> , 2021, 26, 7294.	3.8	12
16	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	4.4	11
17	Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma. <i>Future Oncology</i> , 2020, 16, 9-13.	2.4	3
18	Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. <i>Frontiers in Oncology</i> , 2020, 10, 612385.	2.8	23

#	ARTICLE	IF	CITATIONS
19	Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. International Journal of Molecular Sciences, 2019, 20, 3258.	4.1	38
20	Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes, 2019, 10, 709.	2.4	71
21	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews, 2018, 68, 102-110.	7.7	183
22	Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study.. Journal of Clinical Oncology, 2018, 36, e12629-e12629.	1.6	0
23	Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study. AIMS Medical Science, 2017, 4, 456-464.	0.4	1
24	Biomarkers and prognostic factors for malignant pleural mesothelioma. Future Oncology, 2015, 11, 29-33.	2.4	23
25	Efficacy of mitomycin C plus a fluoropyrimidine in pretreated patients with metastatic colorectal cancer eligible to regorafenib: Results of a retrospective study.. Journal of Clinical Oncology, 2015, 33, e14661-e14661.	1.6	1